Bioventus Q4 2020 Earnings Report
Key Takeaways
Bioventus Inc. reported Q4 2020 net sales of $98.6 million, a 1% increase year-over-year. The company's net income from continuing operations was $2.3 million. Adjusted EBITDA was $28.2 million, down 8% year-over-year.
Net sales increased by 1% year-over-year, reaching $98.6 million.
U.S. net sales increased by 3% year-over-year to $89.7 million, while international net sales decreased by 17% year-over-year to $8.9 million.
Net income from continuing operations decreased by 58% year-over-year to $2.3 million.
Adjusted EBITDA decreased by 8% year-over-year to $28.2 million.
Bioventus
Bioventus
Bioventus Revenue by Geographic Location
Forward Guidance
For the twelve months ending December 31, 2021, the Company expects net sales of $360 million to $372 million, net income attributable to common shareholders of $15 million to $19 million, Non-GAAP net income attributable to common shareholders of $43 million to $46 million, and Adjusted EBITDA of $79 million to $83 million.
Positive Outlook
- Net sales are expected to be between $360 million and $372 million.
- Net income attributable to common shareholders is projected to be $15 million to $19 million.
- Non-GAAP net income attributable to common shareholders is expected to be $43 million to $46 million.
- Adjusted EBITDA is anticipated to be $79 million to $83 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income